Again and again, we talk about “mutant genes”, when it frequently and almost inevitably gets to protein structure, as in this case. The protein in this case, and in similar cases behaves as an enzyme with an active site. In this case the binding affinity to the coenzyme is so strong that the conversion of GTP is arrested, with downstream consequences. This is somewhat different than other cancers in that the proliferative malignant neoplasia shows up so early. However, in many cancers, depending on tissue, there are progressive metabolic changes, and the mutation(s) come in later transitions. This may be adaptive, and it has to involve local circulation, proinflammatory effects, and mitochondrial function that gives way to reversal from catabolic to anabolic activity (reduced ATP production), which leads to reliance on the Warburgh – Pasteur effect. Further progression results in the cannabolization of peripheral muscle by gluconeogenesis to provide glucose. It is really encouraging to come to a step in the analysis where they have gotten back to protein structure and function in this very complicated disease state.
Follow Blog via Email
-
Recent Posts
- Sperm epigenetic clock and pregnancy outcomes May 14, 2022
- Lessons on the Frontier of Gene & Cell Therapy – The Disruptive Dozen 12 #GCT Breakthroughs that are revolutionizing Healthcare May 9, 2022
- Relevance of Twitter.com forthcoming Payment System for Scientific Content Promotion and Monetization May 9, 2022
- Tweets at #WMIF2022 by @pharma_BI & @AVIVA1950 and all Retweets of these Tweets – 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON May 7, 2022
- Data Science: Step by Step – A Resource for LPBI Group’s One-Year Internship in IT, IS, DS May 7, 2022
- 2022 World Medical Innovation Forum, GENE & CELL THERAPY • MAY 2–4, 2022 • BOSTON • IN-PERSON May 1, 2022
- We Celebrate TEN Years of Excellence, LPBI Group: 4/2012 – 4/2022 April 25, 2022
- The durability of T cells versus the triggered of high levels of antibodies: Rationale for the development of T cells focused vaccines April 22, 2022
- The Framingham Study: Across 6 Decades, Cardiovascular Disease Among Middle-Aged Adults – mean life expectancy increased and the RLR of ASCVD decreased. Effective primary prevention efforts and better screening increased. April 22, 2022
- TricValve Transcatheter Bicaval Valves System – Interventional cardiologists at Cleveland Clinic have successfully completed the first implantation in North America April 20, 2022
Archives
Categories
Meta
-
2012pharmaceutical
-
Amandeep Kaur
-
Aashir Awan, Phd
-
Abhisar Anand
-
Adina Hazan
-
Alan F. Kaul, PharmD., MS, MBA, FCCP
-
alexcrystal6
-
anamikasarkar
-
apreconasia
-
aviralvatsa
-
David Orchard-Webb, PhD
-
danutdaagmailcom
-
Demet Sag, Ph.D., CRA, GCP
-
Dror Nir
-
dsmolyar
-
Ethan Coomber
-
evelinacohn
-
Gail S Thornton
-
Irina Robu
-
jayzmit48
-
jdpmd
-
jshertok
-
kellyperlman
-
Ed Kislauskis
-
larryhbern
-
Madison Davis
-
marzankhan
-
megbaker58
-
ofermar2020
-
Dr. Pati
-
pkandala
-
Rosalind Codrington, PhD
-
ritusaxena
-
Rick Mandahl
-
sjwilliamspa
-
Srinivas Sriram
-
stuartlpbi
-
Dr. Sudipta Saha
-
tildabarliya
-
vaishnavee24
-
zraviv06
-
zs22
-
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.